Overview

• The real-world study of 411 adults on incretin therapies for at least three months, presented at EASD and published in Diabetes, Obesity and Metabolism, found 21.3% reported heightened sweetness and 22.6% increased saltiness, with bitterness and sourness unchanged.
• Participants who noticed sweeter taste were about twice as likely to report feeling full sooner, 67% more likely to report reduced appetite, and 85% more likely to report fewer cravings.
• Those who perceived greater saltiness were roughly twice as likely to report increased satiety compared with participants who noted no change in saltiness.
• Reports of saltier taste were most common among Wegovy users at 26.7% versus 16.2% for Ozempic and 15.2% for Mounjaro, while increases in sweetness were similar across drugs.
• Adjusted BMI reductions were 17.4% with Ozempic, 17.6% with Wegovy, and 15.5% with Mounjaro, yet the study found no association between taste changes and BMI loss and noted limitations including self-reported data and non-causal design.